Comparative Effectiveness of Individual Versus Group-Level Interventions to Increase PrEP Uptake and Reduce HIV/STI Incidence

Comparative Effectiveness of Individual Versus Group-level Interventions to Reduce HIV Risk Among African Immigrant Women

The HIV diagnosis rate among African-born Black women is the highest of all Black individuals living in the US. Correct and consistent use of condoms and use of pre-exposure prophylaxis (PrEP) are two effective means of decreasing HIV risk among women, but they remain suboptimal among Black women.

The specific aims of this study are:

1. To culturally adapt two widely utilized, evidence-based HIV prevention interventions originally designed for US born Black women (Sister-to-Sister (S2S) and Sisters Informing Sisters about Topics on AIDS (SISTA)) for use by African-born women.

   To ensure the interventions resonated with African culture, they were given new names. The adapted S2S program was renamed as 'Dada Kwa Dada' (DKD), and the SISTA adaptation as 'DADA.' In Swahili and various other languages across East and West Africa, 'dada' means 'sister'.

2. To conduct a randomized controlled comparative effectiveness trial (RCT) to determine the effectiveness of adapted versions of S2S versus SISTA on increasing condom use and PrEP uptake among African-born women.

This study compares the effectiveness of an individual versus a group-level intervention to increase pre-exposure prophylaxis (PrEP) uptake, condom use, and HIV testing and decrease the incidence of HIV and other sexually transmitted infections (STIs).

Study Overview

• Status: Completed
• Conditions: HIV; Other STIs
• Intervention / Treatment: Behavioral: Dada Kwa Dada (individual-level); Behavioral: DADA (group-level)

Detailed Description

Background and Significance

The HIV diagnosis rate among African-born (immigrant, foreign-born) Black women is the highest of all Black individuals living in the US. Nationally, the 2014 HIV diagnosis rate among African-born Black women was 100.5 per 100,000-a rate 400% (5.3 times) higher than US-born Black women (19.1), 1.4 times the rate of US-born Black men (72.8), and 2.0 times the rate of African-born men (51.3). While the rate of new HIV diagnoses among all Black women has decreased significantly overall, the disparity between African-born and US-born Black women has increased. More than half of newly diagnosed African-born Black individuals are women (60.7%), compared to 27.0% among the US-born Black population.

In Massachusetts (MA), a proposed multi-site study location, 70% of new HIV diagnoses among Black women are among non-US born women (60% African-born). In New York City (NYC), 34% of recently diagnosed women were non-US born, with 23% from Africa. Crucially, a significant proportion of HIV transmission among African-born women occurs post-immigration within the US. Phylogenetic and qualitative analyses indicate that between 30% and 62% of HIV-infected African-born individuals most likely contracted the virus in the US.

HIV risk among African-born Black women is driven by complex cultural, psychosocial, and structural factors along a defined causal pathway. These include culturally based gender inequalities, high levels of HIV-related stigma, knowledge deficits, acculturative stress, intimate partner violence (IPV), low socioeconomic and undocumented immigration status, and culturally specific sexual practices like "dry sex". Despite their vulnerability, correct condom use and the uptake of Pre-Exposure Prophylaxis (PrEP) are suboptimal. The key evidence gap is that no culturally-appropriate, evidence-based interventions have been developed or adapted to increase condom use and PrEP uptake specifically for diverse African-born women.

Significance This study is designed to address a critical gap and inform an important decisional dilemma for stakeholders and community-based organizations (CBOs) by comparing the effectiveness of two distinct HIV/STI prevention interventions. Sister-to-Sister (S2S) is a brief (20-minute), individual-level, health professional-led intervention focused on skill-building and condom usage. SISTA (Sisters Informing Sisters about Topics on AIDS) is a peer-led, group-level intervention utilizing the Theory of Gender and Power to overcome gender inequality and promote ethnic pride.

By culturally adapting these interventions, the study aligns with national efforts to "End the HIV Epidemic." The project builds upon the infrastructure of Tulumbe! ("Let's Engage"), a PCORI-funded partnership of over 70 African-born patients, clinicians, and stakeholders. The community identified three primary objectives that this study addresses: (1) increase safer sex/testing among youth/young adults, (2) increase self-efficacy for HIV prevention to overcome gender inequality, and (3) reduce HIV stigma. We hypothesize that the culturally adapted SISTA (renamed DADA, meaning "Sister" in Swahili) will be more effective than the culturally adapted S2S (renamed Dada Kwa Dada or DKD) because it targets gender inequality, is peer-led, and fosters community support.

Specific Aims and Objectives The central research question is: What effect does participation in a culturally-adapted group-level versus an individual-level intervention have on the use of HIV prevention strategies among at-risk African-born women living in the US?

• Specific Aim 1 (Cultural Adaptation and Pilot Test): To culturally adapt two widely utilized, evidence-based HIV prevention interventions originally designed for US-born Black women (S2S and SISTA) utilizing a revised 7-step ADAPT-ITT framework. This aim includes conducting focus groups and a pilot test to determine feasibility and acceptability prior to the comparative effectiveness trial.
• Specific Aim 2 (Comparative Effectiveness RCT): To conduct a randomized controlled comparative effectiveness trial (RCT) of the culturally adapted versions of S2S (DKD) versus SISTA (DADA) to determine their effectiveness in increasing condom use and PrEP uptake (two patient-centered primary outcomes) among African-born women.

Subject Selection Participants will be African-born cisgender women, ages 18 to 45, who are fluent in English or French. Eligibility criteria dictate that participants must self-identify as Black or mixed race, report condomless vaginal or anal sex with one or more males in the last 3 months prior to enrollment, and have an HIV-negative or unknown status (offered testing at baseline). Pregnant women are explicitly excluded as there is no data regarding the selected interventions in pregnancy.

The study spans sites in MA and NYC. The clinical trial components (Aim 2) will take place through the Brigham and Women's Hospital (BWH) Clinic and Whittier Street Health Center (WSHC) in MA, and the Muslim Women's Institute for Research and Development (MWIRD) in NYC. WSHC serves roughly 8,793 African immigrant women annually (47% of clientele), and MWIRD serves 1,755 (with >40% French-speaking). The adaptation phase (Aim 1) involves the Multicultural AIDS Coalition (MAC) in MA and the African Services Committee (ASC) in NYC.

Recruitment Strategy

Recruitment will follow the MGB IRB-approved protocol #2023P001336. A multi-pronged strategy will be employed by study coordinators and African-born Patient Investigators:

1. Study Advertisements: Flyers will be posted in clinical waiting areas, CBOs (e.g., MAC, Harvard Street Neighborhood Health Center), African grocery stores, and restaurants. Online social media groups, radio, and mass transit ads will also be utilized.
2. Study Outreach: Research Assistants (RAs) will attend 1-2 social gatherings/events monthly sponsored by African community organizations to describe the study.
3. Participant Referrals (Snowballing): The study leverages community networks by offering a $10 referral incentive for any current participant (or non-participant) who refers an eligible candidate (up to $30 maximum for three or more referrals).
4. Provider Referrals: Health care providers at BWH, WSHC, and MWIRD will inform eligible patients and provide contact information.

Randomization Process and Treatment Assignment The study utilizes a blocked 1:1 randomization design with stratification by site, African region of origin (West vs. East Africa, the most common regions of origin), and language (English vs. French). The biostatistician will use a random number generator to devise a randomization log via REDCap. To prevent anticipation of the condition, alternating blocks of 2 and 4 will be used.

Once randomized via REDCap, DADA participants will wait to be scheduled into a session until at least 4 additional participants within their site and language group have been randomized to form a cohort of 5-8 women. This group size is purposefully kept small to enhance opportunities for pro-social, peer feedback regarding sexual health behavior. We anticipate that both interventions will be delivered approximately two weeks post-enrollment.

Study Procedures Due to the COVID-19 pandemic, intervention delivery will occur entirely virtually via Zoom. Upon enrollment and consent, participants complete an online REDCap survey.

• DKD (Individual-Level): A brief (approximately 1 to 1.5 hours) skill-building session delivered by study team staff in English or French.
• DADA (Group-Level): A comprehensive peer-led intervention delivered across two 3-hour sessions, designed to reflect African cultural norms, poetry, and storytelling.

Participants are followed at 3 and 6 months. To increase the validity of self-reported condom use, participants will be provided a daily calendar to document sexual activity (focusing on 30-day data). HIV testing (4th generation assay) and STI testing (urine nucleic acid amplification for Chlamydia and Gonorrhea) are required at baseline and 6 months. Participants may choose in-person lab visits (covering transport or a $25 reimbursement), use mailed self-test kits, or provide official lab results from the past 3 months.

Compensation includes stipends for data plans. To encourage completion of the lengthy group sessions, DADA participants receive $120 at baseline, while DKD participants receive $50. Both groups receive $25 at the 3- and 6-month follow-ups, along with intervention completion certificates.

Sample Size and Power The RCT targets a total sample size of 120 participants (60 per condition), accounting for an estimated 10% dropout rate. Based on prior data, baseline condom use is estimated at 22%.

• Condom Use: Assuming a 26% increase in the DKD arm and a 53% increase in the DADA arm at 6 months, 120 participants provides 80% power to detect a statistically significant difference (alpha = 0.05).
• PrEP Uptake: The sample provides 80% power to detect a difference of 10% increased uptake in the DKD arm versus 33% in the DADA arm.
• STI Incidence: With 60 per arm, differences of 20% STI incidence in the DKD arm versus 2% in the DADA arm can be detected with 80% power.

These calculations account for site-level clustering using an intraclass correlation coefficient (ICC) of 0.005 and a design effect of 1.175. The team projects screening 928 individuals, with 474 (50%) eligible, to achieve the target 120.

Internal and External Validity Internal validity is safeguarded through multiple mechanisms: selection bias is minimized by the block randomization design; attrition bias is controlled by adhering strictly to an intention-to-treat (ITT) approach; and performance bias is mitigated by recording interventions and conducting ongoing supervision. Contamination is reduced by requesting participants not to share information.

External validity is highly robust. The study recruits from massive target populations (>100,000 African-born in MA, >145,000 in NYC). The interventions are based in real-world CBO and clinical settings, and the eligibility criteria capture a diverse cross-section of women with varying degrees of HIV/STI risk. By heavily involving community stakeholders and Patient Investigators throughout the adaptation and implementation phases, the study ensures the findings are highly generalizable and ready for national scale-up.

Heterogeneity of Treatment Effects (HTE) The study will estimate intervention effects across clinically relevant subgroups, particularly regional origin (West vs. East African) and time since immigration (≥10 years vs <10 years). Subgroup analysis will not be conducted based on immigration status due to the high likelihood of missing data surrounding this sensitive variable.

The study acknowledges that a sample size of 120 is statistically underpowered for definitive HTE interaction testing. Assuming two strata of equal size (n=60 per stratum), achieving 80% power to detect statistically significant HTE for condom use would require detecting extreme odds ratio differences of 11.67 versus 1.16. Therefore, while formal interactions will be tested, any clinically meaningful but statistically non-significant stratum-specific differences will be treated strictly as hypothesis-generating data for future larger-scale studies.

Analytic Plan Data will be analyzed using an intention-to-treat (ITT) protocol, analyzing participants in their original assigned conditions regardless of session attendance. Initial unadjusted analyses will use t-tests for continuous variables and chi-square testing for categorical outcomes.

The primary statistical analyses will employ generalized estimating equation (GEE) regression models (linear and logistic) for repeated measures to obtain adjusted mean differences or odds ratios over the 6-month period. Models will adjust for sociodemographic covariates, study site, and age. Because the DADA arm is a group-level intervention (causing clustering) while DKD is individual-level, heteroscedastic partially nested mixed-effects models will be used. Additionally, an "as treated" analysis will assess the DADA arm by dividing subgroups based on their level of dose/compliance to the two 3-hour sessions. All statistical testing will employ a 2-sided type I error rate of 5%.

Monitoring and Quality Assurance Given the behavioral nature of the interventions and the minimal risk profile, a multiple-person Data Safety and Monitoring Board (DSMB) is deemed unnecessary. Instead, an independent, trained mental health provider-Dr. Christina Psaros, a licensed clinical social worker and Associate Professor with research experience-will serve as the independent monitor.

Dr. Psaros will receive periodic reports every 3 months detailing subject enrollment, retention, dropouts (with reasons), and adverse events. She will make formal recommendations regarding the continuation, modification, or termination of the study. Any unexpected, serious adverse events will be reported by telephone by the PI to the IRB and the independent monitor within one business day, followed by a comprehensive written narrative report within 3 business days.

Process (Acceptability and Feasibility) Evaluation Aim 1 incorporates an extensive adaptation and evaluation process using the ADAPT-ITT framework. Virtual focus groups will be held with 68 potential participants (11 groups) and 39 organizational/clinic staff (4 groups) across MA and NYC to assess culturally specific prevention needs. A "theatre test" will feature live mock interventions with trained facilitators and CEAB members to refine the manuals.

Following adaptation, a non-randomized pilot test involving 28 women (14 NYC, 14 MA) will assess feasibility and acceptability. Acceptability will be measured using an adapted Information Systems Success Model (ISSM), evaluating four domains via Likert scales: information quality, delivery quality, perceived usefulness, and overall satisfaction. Feasibility will be evaluated through post-intervention facilitator feedback on session flow and content adequacy.

Fidelity Assessment Intervention fidelity is a critical component and will be evaluated based on three dimensions: (1) Content (was each component implemented as planned?); (2) Coverage (what proportion of the target group participated?); and (3) Frequency/Duration (were components implemented as often and for as long as planned?).

During the pilot and RCT, post-intervention interviews will be conducted with facilitators and participants to capture these metrics. Furthermore, a random sample of 10 recorded Zoom intervention deliveries will be formally reviewed to assess strict adherence to the intervention manual. The team will also evaluate moderators of fidelity, such as intervention complexity, facilitation strategies, and patient responsiveness.

Data Management The Principal Investigator (Bisola Ojikutu) holds ultimate responsibility for data management and safeguarding. All study data will be collected, stored, and managed using REDCap (Research Electronic Data Capture), a secure, HIPAA-compliant web-based application hosted by Partners HealthCare Research Computing. Data will be identified by a unique identification (ID) code and kept entirely separate from study samples, lab results, informed consent documents, and locator information. To prevent bias, the analytical study team will remain blinded to the data and results until the conclusion of the trial.

Preventing and Handling Missing Data Trial design strategies to limit missing data include offering substantial financial incentives, frequent follow-up periods, non-HIV-related contact (e.g., birthday/holiday emails), and leveraging the deep community trust of participating CBOs.

If item nonresponse is substantial, it will be addressed using multiple imputation techniques via PROC MI in SAS, assuming data are missing completely at random (MCAR) or at random (MAR). The team will generate 20 imputed datasets and conduct ITT analyses, combining results using PROC MIANALYZE. If there are statistically significant differences between respondents and non-respondents at follow-up, inverse predicted probability nonresponse weights will be constructed. The team will also randomly impute data in sensitivity analyses to account for non-ignorable missing data scenarios.

Reporting of Subject Enrollment and Follow-up The study is committed to rigorous reporting aligned with the 2010 CONSORT guidelines. The research team will track and report the precise number of patients approached, screened, deemed ineligible, and those refusing participation. Subject attrition and all adverse events will be explicitly noted. For any participant who drops out, the team will thoroughly document the specific reason, who initiated the dropout decision, and whether the dropout pertained to intervention participation, data collection, or both. All included and excluded participants will be accounted for in the final CONSORT diagram.

Clinical monitoring structure/site monitoring plan The study features a highly integrated clinical and site monitoring structure. Site Principal Investigators (e.g., Federica Williams at WSHC, Dr. Nurah Amatullah at MWIRD, Chioma Nnaji at MAC, and Mulusew Bekele at ASC) are responsible for overall site oversight. They supervise local staff, manage recruitment, oversee intervention implementation, facilitate lab testing pathways, and report regularly to the BWH study team.

The Community Engagement Advisory Board (CEAB), comprising community experts, stakeholders, and Tulumbe! members, will meet weekly during Years 1 and 2, and monthly in Year 3. Patient Investigators (African-born women, some living with HIV) will act as peer facilitators, directly managing recruitment, consent, and delivery of the DADA interventions.

Data Sensitivity Because the study collects highly sensitive data (including HIV status, behavioral risks, and undocumented immigration status), stringent protections are in place. Participant names will only appear on written consent forms and a master tracking list. This master list links the unique ID numbers to contact information. It will be stored securely in a locked file cabinet and on a single password-protected, encrypted computer inside a locked office, accessible only to the site PI and coordinating project staff. Furthermore, a federal Certificate of Confidentiality will be obtained. Participants experiencing distress or disclosing Intimate Partner Violence (IPV) will be immediately referred to established counseling and clinical care pathways at WSHC, BWH, or the Institute for Family Health.

Disposition of Data After the Study Hard and soft copies of raw data, the master linking list, and all identifiable participant information will be securely and permanently destroyed within one year following the completion of the study. Audio recordings from the focus groups and qualitative interviews will be destroyed immediately after their transcription accuracy has been verified. De-identified quantitative data sets will be maintained for a reasonable period to allow for the publication of final reports and journal articles, after which they too will be securely destroyed.

Data Integrity Data integrity is foundational to the study's validity. The research team will undergo extensive training to ensure standardized, objective collection and recording of participant information. Site coordinators will rigorously edit and audit all REDCap assessments for legibility, consistency, and completeness. All electronic files will be heavily password-protected, encrypted, and transmitted securely (via encrypted flash drives or MGB Dropbox for business). Paper files will be kept exclusively in locked file cabinets. Mass General Brigham Institutional Review Board will serve as the single IRB, utilizing reliance agreements with the community sites to maintain strict ethical and data integrity oversight throughout the project lifecycle.

• Study Type: Interventional
• Enrollment (Actual): 149
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Brigham and Women's Hospital
    • Roxbury, Massachusetts, United States, 02120
      • Whittier Street Health Center
  • New York
    • The Bronx, New York, United States, 10452
      • Muslim Women's Insitute for Research and Development

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• HIV-negative
• Born in an African country
• Currently living in Greater Boston Area or New York City
• Cis-gender woman
• Self-reported Black or mixed-Black race
• Fluent in English or French
• Ages between 18 and 45
• Report of condomless vaginal or anal sex with one or more male(s) in the last 3 months prior to enrollment

Exclusion Criteria:

- Cis-gender man, transgender woman, transgender man, Pregnant woman

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Individual-level intervention; Virtual one-on-one session	Behavioral: Dada Kwa Dada (individual-level); Dada Kwa Dada (DKD) intervention is an adapted version of Sister to Sister (S2S) intervention (a brief, health profession-led, individual-level intervention proven to increase condom use and decrease STIs among African American women). Intervention is a 1hr to 1.5hrs session and offered in English or French.
Experimental: Group-level intervention; Virtual group sessions	Behavioral: DADA (group-level); DADA intervention is an adapted version of Sisters Informing Sisters about Topics on AIDS (SISTA) intervention (a peer-led, group-level intervention proven to increase condom use and decrease STIs among African American women). This is a 6hrs intervention implemented in two three-hour sessions and offered in English or French.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants who used condom during their last sexual intercourse	Condom use at last sexual intercourse (Self-report yes/no) change from baseline to each followup)	3-month and 6-months after intervention
Proportion of participants who obtained PrEP prescriptions.	Participants who obtained prescription for PrEP (Self-report/medical record review)	3-months and 6-months after intervention
Proportion of participants who are willing to take PrEP in the next 12 months.	Participants who reported that they were extremely unlikely, very unlikely, somewhat unlikely, not sure, somewhat likely, very likely or extremely likely willing to take PrEP.	3-months and 6-months after intervention
Proportion of participants who took PrEP through pill or injection.	Participants who took daily PrEP pills or PrEP injection.	3-months and 6-months after intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants who tested positive for STI.	New diagnosis for HIV, Chlamydia trachomatis and Neisseria gonorrhea.	6-months after intervention
Proportion of participants who accepted HIV testing.	Participants who accepted HIV testing.	6-months after intervention
Proportion of participants with intention to get tested for HIV in the next 6 months.	Participants who reported that they were very unlikely, somewhat unlikely, somewhat likely or very likely to get tested for HIV in the next 6 months.	6-months after intervention

Collaborators and Investigators

• Sponsor: Massachusetts General Hospital
• Collaborators: Harvard Medical School (HMS and HSDM); Patient-Centered Outcomes Research Institute; Boston University; RAND; The Fenway Institute; Muslim Women's Institute for Research and Development; Whittier Street Health Center; Harvard Street Neighborhood Health Center
• Investigators: Principal Investigator: Bisola O. Ojikutu, MD, MPH, Brigham and Women's Hospital; Study Director: Gray M. Maganga, MS, Brigham and Women's Hospital; Study Chair: Laura Bogart, PhD, RAND Corporation Inc; Study Chair: Khady Diouf, MD, Brigham and Women's Hospital

Publications and helpful links

General Publications

• Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, Parikh UM, Piper J, Masse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM; VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015 Feb 5;372(6):509-18. doi: 10.1056/NEJMoa1402269.
• Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017 Jan 26;17(1):88. doi: 10.1186/s12913-017-2031-8.
• Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012 Aug 2;367(5):399-410. doi: 10.1056/NEJMoa1108524. Epub 2012 Jul 11.
• Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012 Oct 4;367(14):1355-60. doi: 10.1056/NEJMsr1203730. No abstract available.
• Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17; quiz CE1-4.
• Briker SM, Aduwo JY, Mugeni R, Horlyck-Romanovsky MF, DuBose CW, Mabundo LS, Hormenu T, Chung ST, Ha J, Sherman A, Sumner AE. A1C Underperforms as a Diagnostic Test in Africans Even in the Absence of Nutritional Deficiencies, Anemia and Hemoglobinopathies: Insight From the Africans in America Study. Front Endocrinol (Lausanne). 2019 Aug 7;10:533. doi: 10.3389/fendo.2019.00533. eCollection 2019.
• Carey MP, Schroder KE. Development and psychometric evaluation of the brief HIV Knowledge Questionnaire. AIDS Educ Prev. 2002 Apr;14(2):172-82. doi: 10.1521/aeap.14.2.172.23902.
• Shaweno D, Tekletsadik E. Validation of the condom use self-efficacy scale in Ethiopia. BMC Int Health Hum Rights. 2013 Apr 23;13:22. doi: 10.1186/1472-698X-13-22.
• Brafford LJ, Beck KH. Development and validation of a condom self-efficacy scale for college students. J Am Coll Health. 1991 Mar;39(5):219-25. doi: 10.1080/07448481.1991.9936238.
• Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM; Partners PrEP Study Team. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014 Jul 23-30;312(4):362-71. doi: 10.1001/jama.2014.8735.
• Horvath KJ, Oakes JM, Rosser BR, Danilenko G, Vezina H, Amico KR, Williams ML, Simoni J. Feasibility, acceptability and preliminary efficacy of an online peer-to-peer social support ART adherence intervention. AIDS Behav. 2013 Jul;17(6):2031-44. doi: 10.1007/s10461-013-0469-1.
• Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014 Sep;18(9):1712-21. doi: 10.1007/s10461-014-0839-3.
• Wingood GM, DiClemente RJ, Villamizar K, Er DL, DeVarona M, Taveras J, Painter TM, Lang DL, Hardin JW, Ullah E, Stallworth J, Purcell DW, Jean R. Efficacy of a health educator-delivered HIV prevention intervention for Latina women: a randomized controlled trial. Am J Public Health. 2011 Dec;101(12):2245-52. doi: 10.2105/AJPH.2011.300340. Epub 2011 Oct 20.
• Demeke HB, Johnson AS, Wu B, Nwangwu-Ike N, King H, Dean HD. Differences Between U.S.-Born and Non-U.S.-Born Black Adults Reported with Diagnosed HIV Infection: United States, 2008-2014. J Immigr Minor Health. 2019 Feb;21(1):30-38. doi: 10.1007/s10903-018-0699-4.
• Adimora AA, Ramirez C, Auerbach JD, Aral SO, Hodder S, Wingood G, El-Sadr W, Bukusi EA; HIV Prevention Trials Network Women at Risk Committee. Preventing HIV infection in women. J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2(0 2):S168-73. doi: 10.1097/QAI.0b013e318298a166.
• Crosby RA, DiClemente RJ, Salazar LF, Wingood GM, McDermott-Sales J, Young AM, Rose E. Predictors of consistent condom use among young African American women. AIDS Behav. 2013 Mar;17(3):865-71. doi: 10.1007/s10461-011-9998-7.
• Wingood GM, DiClemente RJ. Gender-related correlates and predictors of consistent condom use among young adult African-American women: a prospective analysis. Int J STD AIDS. 1998 Mar;9(3):139-45. doi: 10.1258/0956462981921891.
• Huang YA, Zhu W, Smith DK, Harris N, Hoover KW. HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016. MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1147-1150. doi: 10.15585/mmwr.mm6741a3.
• Ojikutu BO, Bogart LM, Higgins-Biddle M, Dale SK, Allen W, Dominique T, Mayer KH. Facilitators and Barriers to Pre-Exposure Prophylaxis (PrEP) Use Among Black Individuals in the United States: Results from the National Survey on HIV in the Black Community (NSHBC). AIDS Behav. 2018 Nov;22(11):3576-3587. doi: 10.1007/s10461-018-2067-8.
• Demeke HB, Johnson AS, Wu B, Moonesinghe R, Dean HD. Unequal Declines in Absolute and Relative Disparities in HIV Diagnoses Among Black Women, United States, 2008 to 2016. Am J Public Health. 2018 Nov;108(S4):S299-S303. doi: 10.2105/AJPH.2018.304641.
• Ojikutu BO, Nnaji C, Sithole-Berk J, Masongo D, Nichols K, Weeks N, Ngminebayihi M, Bishop E, Bogart LM. African born women living with HIV in the United States: unmet needs and opportunities for intervention. AIDS Care. 2018 Dec;30(12):1542-1550. doi: 10.1080/09540121.2018.1497767. Epub 2018 Jul 15.
• Wiewel EW, Torian LV, Hanna DB, Bocour A, Shepard CW. Foreign-Born Persons Diagnosed with HIV: Where are They From and Where Were They Infected? AIDS Behav. 2015 May;19(5):890-8. doi: 10.1007/s10461-014-0954-1.
• Lin HH, Gaschen BK, Collie M, El-Fishaway M, Chen Z, Korber BT, Beatrice ST, Zhang L. Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):399-404. doi: 10.1097/01.qai.0000200663.47838.f1.
• Valverde EE, Oster AM, Xu S, Wertheim JO, Hernandez AL. HIV Transmission Dynamics Among Foreign-Born Persons in the United States. J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):445-452. doi: 10.1097/QAI.0000000000001541.
• Singh GK, Rodriguez-Lainz A, Kogan MD. Immigrant health inequalities in the United States: use of eight major national data systems. ScientificWorldJournal. 2013 Oct 27;2013:512313. doi: 10.1155/2013/512313. eCollection 2013.
• Ojikutu B, Nnaji C, Sithole J, Schneider KL, Higgins-Biddle M, Cranston K, Earls F. All black people are not alike: differences in HIV testing patterns, knowledge, and experience of stigma between U.S.-born and non-U.S.-born blacks in Massachusetts. AIDS Patient Care STDS. 2013 Jan;27(1):45-54. doi: 10.1089/apc.2012.0312. Epub 2012 Dec 21.
• Page LC, Goldbaum G, Kent JB, Buskin SE. Access to regular HIV care and disease progression among black African immigrants. J Natl Med Assoc. 2009 Dec;101(12):1230-6. doi: 10.1016/s0027-9684(15)31134-2.
• De Jesus M, Taylor J, Maine C, Nalls P. A One-Size-Fits-All HIV Prevention and Education Approach?: Interpreting Divergent HIV Risk Perceptions Between African American and East African Immigrant Women in Washington, DC Using the Proximate-Determinants Conceptual Framework. Sex Transm Dis. 2016 Feb;43(2):78-83. doi: 10.1097/OLQ.0000000000000386.
• Okoro ON, Whitson SO. HIV risk and barriers to care for African-born immigrant women: a sociocultural outlook. Int J Womens Health. 2017 Jun 8;9:421-429. doi: 10.2147/IJWH.S129355. eCollection 2017.
• Foley EE. HIV/AIDS and African immigrant women in Philadelphia: structural and cultural barriers to care. AIDS Care. 2005 Nov;17(8):1030-43. doi: 10.1080/09540120500100890.
• De Jesus M. HIV/AIDS and immigrant Cape Verdean women: contextualized perspectives of Cape Verdean community advocates. Am J Community Psychol. 2007 Mar;39(1-2):121-31. doi: 10.1007/s10464-007-9091-6.
• Sabri B. Perspectives on Factors Related to HIV Risk and Preventative Interventions at Multiple Levels: A Study of African Immigrant Women Survivors of Cumulative Trauma. AIDS Educ Prev. 2018 Oct;30(5):419-433. doi: 10.1521/aeap.2018.30.5.419.
• Rosenthal L, Scott DP, Kelleta Z, Zikarge A, Momoh M, Lahai-Momoh J, Ross MW, Baker A. Assessing the HIV/AIDS health services needs of African immigrants to Houston. AIDS Educ Prev. 2003 Dec;15(6):570-80. doi: 10.1521/aeap.15.7.570.24047.
• Worthington C, Este D, Strain KL, Huffey N. African immigrant views of HIV service needs: gendered perspectives. AIDS Care. 2013;25(1):103-8. doi: 10.1080/09540121.2012.687807. Epub 2012 Jun 6.
• Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018 Dec;28(12):850-857.e9. doi: 10.1016/j.annepidem.2018.05.003. Epub 2018 May 18.
• Patel AS, Goparaju L, Sales JM, Mehta CC, Blackstock OJ, Seidman D, Ofotokun I, Kempf MC, Fischl MA, Golub ET, Adimora AA, French AL, DeHovitz J, Wingood G, Kassaye S, Sheth AN. Brief Report: PrEP Eligibility Among At-Risk Women in the Southern United States: Associated Factors, Awareness, and Acceptability. J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):527-532. doi: 10.1097/QAI.0000000000001950.
• Goparaju L, Praschan NC, Warren-Jeanpiere L, Experton LS, Young MA, Kassaye S. Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women. J AIDS Clin Res. 2017 Sep;8(9):730. doi: 10.4172/2155-6113.1000730. Epub 2017 Sep 25.
• Ojikutu BO, Bogart LM, Mayer KH, Stopka TJ, Sullivan PS, Ransome Y. Spatial Access and Willingness to Use Pre-Exposure Prophylaxis Among Black/African American Individuals in the United States: Cross-Sectional Survey. JMIR Public Health Surveill. 2019 Feb 4;5(1):e12405. doi: 10.2196/12405.
• Bazzi AR, Leech AA, Biancarelli DL, Sullivan M, Drainoni ML. Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States. AIDS Patient Care STDS. 2017 Aug;31(8):348-355. doi: 10.1089/apc.2017.0098. Epub 2017 Jul 18.
• Ojikutu BO, Mazzola E, Fullem A, Vega R, Landers S, Gelman RS, Bogart LM. HIV Testing Among Black and Hispanic Immigrants in the United States. AIDS Patient Care STDS. 2016 Jul;30(7):307-14. doi: 10.1089/apc.2016.0120.
• Prosser AT, Tang T, Hall HI. HIV in persons born outside the United States, 2007-2010. JAMA. 2012 Aug 8;308(6):601-7. doi: 10.1001/jama.2012.9046.
• Ojikutu B, Nnaji C, Sithole-Berk J, Bogart LM, Gona P. Barriers to HIV Testing in Black Immigrants to the U.S. J Health Care Poor Underserved. 2014 Aug;25(3):1052-66. doi: 10.1353/hpu.2014.0141.
• Scott-Sheldon LA, Huedo-Medina TB, Warren MR, Johnson BT, Carey MP. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010. J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):489-98. doi: 10.1097/QAI.0b013e31823554d7.
• Schwandt M, Morris C, Ferguson A, Ngugi E, Moses S. Anal and dry sex in commercial sex work, and relation to risk for sexually transmitted infections and HIV in Meru, Kenya. Sex Transm Infect. 2006 Oct;82(5):392-6. doi: 10.1136/sti.2006.019794. Epub 2006 Jun 21.
• Sandala L, Lurie P, Sunkutu MR, Chani EM, Hudes ES, Hearst N. 'Dry sex' and HIV infection among women attending a sexually transmitted diseases clinic in Lusaka, Zambia. AIDS. 1995 Jul;9 Suppl 1:S61-8.
• Kingori C, Esquivel CL, Hassan Q, Elmi A, Mukasa B, Reece M. Recommendations for Developing Contextually Relevant HIV/AIDS Prevention Strategies Targeting African-Born Immigrants and Refugees in the United States. AIDS Patient Care STDS. 2016 Oct;30(10):476-483. doi: 10.1089/apc.2016.0171.
• Airhihenbuwa CO, Webster JD. Culture and African contexts of HIV/AIDS prevention, care and support. SAHARA J. 2004 May;1(1):4-13. doi: 10.1080/17290376.2004.9724822.
• DiClemente RJ, Wingood GM. A randomized controlled trial of an HIV sexual risk-reduction intervention for young African-American women. JAMA. 1995 Oct 25;274(16):1271-6.
• Jemmott LS, Jemmott JB 3rd, O'Leary A. Effects on sexual risk behavior and STD rate of brief HIV/STD prevention interventions for African American women in primary care settings. Am J Public Health. 2007 Jun;97(6):1034-40. doi: 10.2105/AJPH.2003.020271. Epub 2007 Apr 26.
• Wingood GM, Scd, DiClemente RJ. Application of the theory of gender and power to examine HIV-related exposures, risk factors, and effective interventions for women. Health Educ Behav. 2000 Oct;27(5):539-65. doi: 10.1177/109019810002700502.
• Kerani RP, Kent JB, Sides T, Dennis G, Ibrahim AR, Cross H, Wiewel EW, Wood RW, Golden MR. HIV among African-born persons in the United States: a hidden epidemic? J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):102-6. doi: 10.1097/QAI.0b013e3181831806.
• Kerani R, Bennett AB, Golden M, Castillo J, Buskin SE. Foreign-Born Individuals with HIV in King County, WA: A Glimpse of the Future of HIV? AIDS Behav. 2018 Jul;22(7):2181-2188. doi: 10.1007/s10461-017-1914-3.
• Ashton C, Bernhardt SA, Lowe M, Mietchen M, Johnston J. Comparison of HIV/AIDS rates between U.S.-born Blacks and African-born Blacks in Utah, 2000 - 2009. Open AIDS J. 2012;6:156-62. doi: 10.2174/1874613601206010156. Epub 2012 Sep 7.
• Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;(1):CD003255. doi: 10.1002/14651858.CD003255.
• Rinehart DJ, Al-Tayyib AA, Sionean C, Whitesell NR, Dreisbach S, Bull S. Assessing the Theory of Gender and Power: HIV Risk Among Heterosexual Minority Dyads. AIDS Behav. 2018 Jun;22(6):1944-1954. doi: 10.1007/s10461-017-1983-3.
• Koku EF, Rajab-Gyagenda WM, Korto MD, Morrison SD, Beyene Y, Mbajah J, Ashton C. HIV/AIDS among African Immigrants in the U.S.: The Need for Disaggregating HIV Surveillance Data by Country of Birth. J Health Care Poor Underserved. 2016;27(3):1316-29. doi: 10.1353/hpu.2016.0128.
• Cederbaum JA, Song A, Hsu HT, Tucker JS, Wenzel SL. Adapting an evidence-based intervention for homeless women: engaging the community in shared decision-making. J Health Care Poor Underserved. 2014 Nov;25(4):1552-70. doi: 10.1353/hpu.2014.0188.
• Wenzel SL, Cederbaum JA, Song A, Hsu HT, Craddock JB, Hantanachaikul W, Tucker JS. Pilot Test of an Adapted, Evidence-Based HIV Sexual Risk Reduction Intervention for Homeless Women. Prev Sci. 2016 Jan;17(1):112-21. doi: 10.1007/s11121-015-0575-6.
• Wingood GM, Simpson-Robinson L, Braxton ND, Raiford JL. Design of a faith-based HIV intervention: successful collaboration between a university and a church. Health Promot Pract. 2011 Nov;12(6):823-31. doi: 10.1177/1524839910372039. Epub 2011 Apr 21.
• Wingood GM, Robinson LR, Braxton ND, Er DL, Conner AC, Renfro TL, Rubtsova AA, Hardin JW, Diclemente RJ. Comparative effectiveness of a faith-based HIV intervention for African American women: importance of enhancing religious social capital. Am J Public Health. 2013 Dec;103(12):2226-33. doi: 10.2105/AJPH.2013.301386. Epub 2013 Oct 17.
• Cavanaugh CE, Campbell J, Braxton N, Harvey J, Wingood G. Adapting an Evidence-Based HIV-Prevention Intervention for Women in Domestic Violence Shelters. Psychol Violence. 2016 Jul;6(3):469-477. doi: 10.1037/vio0000042.
• Saleh-Onoya D, Braxton ND, Sifunda S, Reddy P, Ruiter R, van den Borne B, Walters TP, Lang D, Wingood GM. SISTA South Africa: the adaptation of an efficacious HIV prevention trial conducted with African-American women for isiXhosa-speaking South African women. SAHARA J. 2008 Dec;5(4):186-91. doi: 10.1080/17290376.2008.9724918.
• Wingood GM, Reddy P, Lang DL, Saleh-Onoya D, Braxton N, Sifunda S, DiClemente RJ. Efficacy of SISTA South Africa on sexual behavior and relationship control among isiXhosa women in South Africa: results of a randomized-controlled trial. J Acquir Immune Defic Syndr. 2013 Jun 1;63 Suppl 1(0 1):S59-65. doi: 10.1097/QAI.0b013e31829202c4.
• Nnaji C, Slopadoe S, Rao T, Babirye J, Pwamang A. Safety Net Party: A Group-Based Program to Prevent HIV/STDs in African-Born Women in the United States. J Assoc Nurses AIDS Care. 2016 Sep-Oct;27(5):731-9. doi: 10.1016/j.jana.2016.04.009. Epub 2016 May 6. No abstract available.
• Johnson-Agbakwu CE, Flynn P, Asiedu GB, Hedberg E, Breitkopf CR. Adaptation of an Acculturation Scale for African Refugee Women. J Immigr Minor Health. 2016 Feb;18(1):252-62. doi: 10.1007/s10903-014-9998-6.
• Fonner VA, Kennedy CE, O'Reilly KR, Sweat MD. Systematic assessment of condom use measurement in evaluation of HIV prevention interventions: need for standardization of measures. AIDS Behav. 2014 Dec;18(12):2374-86. doi: 10.1007/s10461-013-0655-1.
• Jennings L, Rompalo AM, Wang J, Hughes J, Adimora AA, Hodder S, Soto-Torres LE, Frew PM, Haley DF; HIV Prevention Trials Network (HPTN 064) Women's HIV SeroIncidence Study (ISIS). Prevalence and correlates of knowledge of male partner HIV testing and serostatus among African-American women living in high poverty, high HIV prevalence communities (HPTN 064). AIDS Behav. 2015 Feb;19(2):291-301. doi: 10.1007/s10461-014-0884-y.
• Calabrese SK, Willie TC, Galvao RW, Tekeste M, Dovidio JF, Safon CB, Blackstock O, Taggart T, Kaplan C, Caldwell A, Kershaw TS. Current US Guidelines for Prescribing HIV Pre-exposure Prophylaxis (PrEP) Disqualify Many Women Who Are at Risk and Motivated to Use PrEP. J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):395-405. doi: 10.1097/QAI.0000000000002042.
• Ojikutu BO, Mayer KH. Hidden in Plain Sight: Identifying Women Living in the United States Who Could Benefit From HIV Preexposure Prophylaxis. J Infect Dis. 2020 Oct 1;222(9):1428-1431. doi: 10.1093/infdis/jiz416.
• Meadowbrooke CC, Veinot TC, Loveluck J, Hickok A, Bauermeister JA. Information Behavior and HIV Testing Intentions Among Young Men at Risk for HIV/AIDS. J Assoc Inf Sci Technol. 2014 Mar;65(3):609-620. doi: 10.1002/asi.23001.
• Peragallo Montano N, Cianelli R, Villegas N, Gonzalez-Guarda R, Williams WO, de Tantillo L. Evaluating a Culturally Tailored HIV Risk Reduction Intervention Among Hispanic Women Delivered in a Real-World Setting by Community Agency Personnel. Am J Health Promot. 2019 May;33(4):566-575. doi: 10.1177/0890117118807716. Epub 2018 Oct 24.
• Asante KO, Doku PN. Cultural adaptation of the condom use self efficacy scale (CUSES) in Ghana. BMC Public Health. 2010 Apr 30;10:227. doi: 10.1186/1471-2458-10-227.
• Herek GM, Capitanio JP. Public reactions to AIDS in the United States: a second decade of stigma. Am J Public Health. 1993 Apr;83(4):574-7. doi: 10.2105/ajph.83.4.574.
• Quinn-Nilas C, Milhausen RR, Breuer R, Bailey J, Pavlou M, DiClemente RJ, Wingood GM. Validation of the Sexual Communication Self-Efficacy Scale. Health Educ Behav. 2016 Apr;43(2):165-71. doi: 10.1177/1090198115598986. Epub 2015 Aug 17.
• Wingood GM, DiClemente RJ. Partner influences and gender-related factors associated with noncondom use among young adult African American women. Am J Community Psychol. 1998 Feb;26(1):29-51. doi: 10.1023/a:1021830023545.
• Ejiogu N, Norbeck JH, Mason MA, Cromwell BC, Zonderman AB, Evans MK. Recruitment and retention strategies for minority or poor clinical research participants: lessons from the Healthy Aging in Neighborhoods of Diversity across the Life Span study. Gerontologist. 2011 Jun;51 Suppl 1(Suppl 1):S33-45. doi: 10.1093/geront/gnr027.
• Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017 Jan 14;31(2):213-232. doi: 10.1097/QAD.0000000000001313.
• Joseph Davey DL, Pintye J, Baeten JM, Aldrovandi G, Baggaley R, Bekker LG, Celum C, Chi BH, Coates TJ, Haberer JE, Heffron R, Kinuthia J, Matthews LT, McIntyre J, Moodley D, Mofenson LM, Mugo N, Myer L, Mujugira A, Shoptaw S, Stranix-Chibanda L, John-Stewart G; PrEP in Pregnancy Working Group. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? J Int AIDS Soc. 2020 Jan;23(1):e25426. doi: 10.1002/jia2.25426.
• Heffron R, Mugo N, Hong T, Celum C, Marzinke MA, Ngure K, Asiimwe S, Katabira E, Bukusi EA, Odoyo J, Tindimwebwa E, Bulya N, Baeten JM; Partners Demonstration Project and the Partners PrEP Study Teams. Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. AIDS. 2018 Jul;32(12):1707-1713. doi: 10.1097/QAD.0000000000001867.
• Dettinger JC, Kinuthia J, Pintye J, Abuna F, Begnel E, Mugwanya K, Sila J, Lagat H, Baeten JM, John-Stewart G. Perinatal outcomes following maternal pre-exposure prophylaxis (PrEP) use during pregnancy: results from a large PrEP implementation program in Kenya. J Int AIDS Soc. 2019 Sep;22(9):e25378. doi: 10.1002/jia2.25378.
• Desrosiers A, Levy M, Dright A, Zumer M, Jallah N, Kuo I, Magnus M, Siegel M. A Randomized Controlled Pilot Study of a Culturally-Tailored Counseling Intervention to Increase Uptake of HIV Pre-exposure Prophylaxis Among Young Black Men Who Have Sex with Men in Washington, DC. AIDS Behav. 2019 Jan;23(1):105-115. doi: 10.1007/s10461-018-2264-5.
• Moitra E, van den Berg JJ, Sowemimo-Coker G, Chau S, Nunn A, Chan PA. Open pilot trial of a brief motivational interviewing-based HIV pre-exposure prophylaxis intervention for men who have sex with men: preliminary effects, and evidence of feasibility and acceptability. AIDS Care. 2020 Mar;32(3):406-410. doi: 10.1080/09540121.2019.1622644. Epub 2019 May 25.
• Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2001;2002(3):CD003255. doi: 10.1002/14651858.CD003255.

Study record dates

Study Major Dates

• Study Start (Actual): November 2, 2023
• Primary Completion (Actual): January 26, 2026
• Study Completion (Actual): January 26, 2026

Study Registration Dates

• First Submitted: August 28, 2023
• First Submitted That Met QC Criteria: August 28, 2023
• First Posted (Actual): September 5, 2023

Study Record Updates

• Last Update Posted (Actual): February 27, 2026
• Last Update Submitted That Met QC Criteria: February 25, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: HIV; Pre-exposure Prophylaxis; Condom use; African-born women
• Other Study ID Numbers: 2023P001336; 125110 (Other Identifier: BWH)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No